

AHF review questions

1. In people with suspected (or under investigation for) acute heart failure, is the addition of natriuretic peptides to the standard initial investigations (using ECG, chest x-ray and blood tests) more accurate compared to standard initial investigations, clinical judgement and each other?
2. In adults with suspected acute heart failure does early echocardiography compared to later echocardiography in addition to standard investigations (using ECG, chest x-ray and blood tests) improve outcome?
3. Is the addition of invasive monitoring more clinically/cost-effective over and above non-invasive monitoring to improve outcome?
4. In people with confirmed acute heart failure and cardiogenic pulmonary oedema is non-invasive positive pressure ventilation (CPAP and/or bilevel NIPPV) more clinical and cost effective than standard medical care alone to improve outcome?
5. What are the predictors of outcome in mechanically ventilated acute heart failure patients?
6. In patients with acute heart failure are opiates as an adjunct to other first line pharmacological therapies more clinically and cost effective compared to other pharmacological treatments alone?
7. In patients with acute heart failure which diuretic administration strategy is the most clinically/cost-effective to improve outcome?
8. In patients with acute heart failure are vasodilators more clinically or cost effective than placebo to improve clinical outcomes?
9. In patients with acute heart failure are inotropes or vasopressors safe and clinically / cost effective compared to standard medical treatment or each other to improve outcome?
10. In people with confirmed acute heart failure and cardiogenic pulmonary oedema is non-invasive positive pressure ventilation (CPAP and/or bilevel NIPPV) more clinical and cost effective than standard medical care alone to improve outcome?
11. What are the predictors of outcome in mechanically ventilated acute heart failure patients?
12. In patients with acute heart failure is ultrafiltration more clinical / cost effective than diuretic therapy alone or in addition to diuretic therapy to improve outcome?
13. In people with acute heart failure already on beta-blocker therapy should beta-blockers be reduced or discontinued, and if so should they be reinstated in hospital after stabilisation?
14. For people with confirmed acute heart failure not already on beta-blocker therapy should beta-blocker treatment commence in hospital after stabilisation or following discharge?
15. For people with confirmed acute heart failure not already on angiotensin converting enzyme (ACE)-inhibitor therapy, should ACE inhibitor therapy commence in hospital or following discharge?
16. For people with confirmed acute heart failure not already on mineralocorticoid receptor antagonists (MRAs) should MRA therapy commence in hospital after stabilization or following discharge?
17. For people with aortic stenosis are percutaneous or surgical valvular interventions more clinically or cost effective compared to best medical therapy or each other?

- 18. For people with heart failure with mitral regurgitation, are surgical valvular or percutaneous interventions more clinically or cost effective compared to best medical therapy or each other?**
- 19. For people with acute heart failure is intra-aortic balloon counterpulsation more clinically / cost effective compared to left ventricular assist devices, medical care alone or with each other?**
- 20. For people with suspected or confirmed acute heart failure is a specialist management unit more clinically/cost effective than general medical hospital care?**